Adial Pharmaceuticals Inc (ADIL) - Total Liabilities
Based on the latest financial reports, Adial Pharmaceuticals Inc (ADIL) has total liabilities worth $1.51 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Adial Pharmaceuticals Inc to track the company's year-over-year net asset growth rate.
Adial Pharmaceuticals Inc - Total Liabilities Trend (2015–2025)
This chart illustrates how Adial Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Adial Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Adial Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
JPMorgan Global Emerging Markets Investment Trust PLC
LSE:JEMI
|
UK | GBX31.82 Million |
|
Mecanica Sa Ce
RO:MECF
|
Romania | RON9.52 Million |
|
Trinity Freehold & Leasehold PRP Fund
BK:TNPF
|
Thailand | ฿847.93K |
|
Adcore Inc
TO:ADCO
|
Canada | CA$8.23 Million |
|
LCK Global Kedaton
JK:LCKM
|
Indonesia | Rp7.14 Billion |
|
Silla Sg Co. Ltd
KQ:025870
|
Korea | ₩33.67 Billion |
|
Haidemenos S.A.
AT:HAIDE
|
Greece | €14.64 Million |
|
Belararox Ltd
AU:BRX
|
Australia | AU$4.97 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Adial Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Adial Pharmaceuticals Inc (ADIL) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Adial Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Adial Pharmaceuticals Inc (2015–2025)
The table below shows the annual total liabilities of Adial Pharmaceuticals Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.52 Million | +55.96% |
| 2024-12-31 | $975.86K | +49.32% |
| 2023-12-31 | $653.51K | -73.39% |
| 2022-12-31 | $2.46 Million | -40.47% |
| 2021-12-31 | $4.13 Million | +174.09% |
| 2020-12-31 | $1.51 Million | +179.26% |
| 2019-12-31 | $539.05K | +108.96% |
| 2018-12-31 | $257.97K | -75.00% |
| 2017-12-31 | $1.03 Million | +304.71% |
| 2016-12-31 | $255.02K | +380.44% |
| 2015-12-31 | $53.08K | -- |
About Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid p… Read more